Patients come in all sizes and shapes, and with varying tolerance for complications and risk. Is it plausible that a single dosing regimen can optimize treatment for everybody? If not, what is keeping the pharmaceutical industry from endorsing a more dynamic and patient-centered drug dosing regimen?
Our guest is Dr. David Norris, a physician, mathematician, and inventor. David operates a scientific and statistical consultancy focused on methodology development for precision-medicine applications. He developed Dose Titration Algorithm Tuning (DTAT), a methodological framework that conceives dose individualization as a seamless learning process, beginning in early-phase trials and continuing throughout the drug development process. Before earning his M.D. at Brown University, he worked in diverse application areas including mathematical finance, operations research and systems engineering.
- Norris DC. Dose Titration Algorithm Tuning (DTAT) should supersede ‘the’ Maximum Tolerated Dose (MTD) in oncology dose-finding trials. F1000Research. 2017 (open access)
- Norris DC. One-size-fits-all dosing in oncology wastes money, innovation and lives. Drug Discovery Today. 2018 (open access)
- Norris DC. Precautionary Coherence Unravels Dose Escalation Designs. bioRxiv. 2017 (open access)
WATCH ON YOUTUBE:
Watch the episode on our YouTube channel.